You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創業板連日震盪,多隻個股觸及盤中臨停
格隆匯 08-25 11:01

來源:金十數據

北京時間週二上午A股開盤後,創業板指再次發生異動。創業板註冊制次新股概念板塊跌幅居前,但很快便扭轉頹勢。C康泰在一度跌超30%迅速反彈較開盤價漲30%,觸及盤中臨停。恢復交易後,C康泰繼續拉昇,現已轉漲。

除此之外,創業板股天山生物再度漲20%,蒙泰高新大漲近29%,較開盤價漲30%,兩隻個股均觸發臨停;金春股份、聖元環保等漲逾15%。

值得一提的是,昨天康泰醫學的股價也出現巨幅震盪。

數據顯示,在14:28分和14:41分連續2次觸發臨停後,康泰股價最高觸及308元,漲幅一度擴大至2931%

而在午盤接近尾聲時(14:51左右),康泰股價再度拉昇後快速回落,臨近收盤三分鐘內,振幅高達1790.58%

截至收盤,康泰醫學股價漲幅錄得1061%,報118元,成交額15.7億,換手率達68.61%。

值得一提的是,創業板多隻個股在這兩個交易日均大起大落,從整體漲幅來看,週一18只註冊制新股有10只股票漲幅超過100%,除康泰醫學之外,卡倍億漲幅也非常大,收盤上漲達743%。 

針對康泰醫藥股價的大起大落,有分析師向投資者發出了警告:

週一尾盤時段,康泰醫藥股價快速拉昇並沒有伴隨成交量的放大,這或許是因為流通盤中的賣方已經幾乎耗盡籌碼,導致尾盤直接上演了逼空行情。

在昨日暴漲之後,康泰醫學一躍成為市場熱點,但部分對康泰有深入瞭解的分析師,就對該股的後市走勢提出了一點擔憂。

根據招股書提供的資料,血氧類及紅外體温計產品貢獻了康泰醫學主要的營收,而且外銷收入佔比超過七成。如今隨着疫情逐漸得到控制,部分醫療器械產品的需求可能會明顯回落,這對康泰的業績是一個很大的打擊。其中,康泰醫學的外銷收入中大約有三成來源於美國,比例最高。受國際形勢影響,國際貿易環境趨緊,康泰的未來充滿不確定性。

此外,也有市場分析認為,康泰所在的醫療器械行業毛利率水平在業內也處於一般水平,盈利能否撐起股價的暴漲仍是未知之數。

而對於大盤走勢,有分析師表示:

“在首批創業板註冊制股票上市之際,創業板指數週一總體表現平穩,盤中一度小幅調整,但此後快速恢復上行。週二則高開高走,目前沒有出現明顯異動,前景值得信賴。

數據顯示,週一全天創業板成交額 達2289億元,較上一交易日明顯放大。但由於多隻個股連日震盪,大盤走勢難免也會受到影響,投資者不可掉以輕心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account